Titan Pharmaceuticals Stock Jumps 23% Following Merger Approval

Titan Pharmaceuticals, Inc. experienced a remarkable surge in its stock price, rising 23% in after-hours trading on Tuesday, reaching $6.15 per share. This increase followed the overwhelming approval of a significant three-way merger by its stockholders. The biopharmaceutical company, which closed regular trading at $5.00, saw the spike in investor interest after a special meeting where stockholders voted in favor of the merger with Black Titan Corporation and TalenTec Sdn. Bhd.

Stockholder Approval and Voting Results

According to a filing with the Securities and Exchange Commission, stockholders voted decisively at the special meeting held on Monday. The results for the Business Combination Proposal were as follows:

– Votes in Favor: 730,383
– Votes Against: 1,860
– Abstentions: 1,902
– Total Votes Cast: 734,145
– Percentage of Outstanding Shares Voted: 55.19%

The approval signals strong backing from investors for the merger, which aims to expand Titan’s capabilities and market reach.

Market Impact and Future Steps

The significant after-hours surge reflects a positive outlook among investors regarding the strategic implications of the merger. Titan Pharmaceuticals, based in California, has faced notable volatility in its stock price over the past year, moving between $3.03 and $6.99. Currently, the company maintains a market capitalization of approximately $6.70 million and an average daily trading volume of 39,920 shares.

Before the merger announcement, Titan stock had shown a modest gain of 1.11% during regular trading hours, closing at $5.00 after adding $0.055 to its previous value. Additionally, results for the Nasdaq Proposal and the Adjournment Proposal showed overwhelming approval, with the following tallies:

– Nasdaq Proposal: Votes For: 730,049; Votes Against: 2,127; Abstentions: 1,969
– Adjournment Proposal: Votes For: 729,943; Votes Against: 3,808; Abstentions: 394

The merger remains contingent on meeting certain closing conditions, including obtaining approval for listing Black Titan ordinary shares on the Nasdaq Stock Market. The original agreement for the merger and exchange of shares was established on August 19, 2024.

Investor sentiment remains high as the company navigates this pivotal moment in its business trajectory, suggesting a potentially transformative phase for Titan Pharmaceuticals and its stakeholders.